Landos Biopharma, Inc.
LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS

Last updated:

Abstract:

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Status:
Application
Type:

Utility

Filling date:

20 Oct 2020

Issue date:

18 Feb 2021